Generation and characterization of humanized mice carrying COMT158 Met/Val alleles

Neuropsychopharmacology

Volumn 39, Issue 8, 2014, Pages 1823-1832

  Risbrough, Victoria ^a,b   Ji, Baohu ^a   Hauger, Richard ^a,b   Zhou, Xianjin ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; TOLCAPONE; COMT PROTEIN, HUMAN; METHIONINE; VALINE;

ALLELE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; FEAR; FEMALE; GENE TARGETING; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; MALE; MEMORY DISORDER; MOUSE; MOUSE MODEL; NEUROPSYCHIATRY; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; SENSORY GATING; SEX DIFFERENCE; SIBLING; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; WORKING MEMORY; ANIMAL; EXPLORATORY BEHAVIOR; GENETICS; HUMAN; LEARNING; MEMORY; PHYSIOLOGY; TRANSGENIC MOUSE;

ALLELES; ANIMALS; CATECHOL O-METHYLTRANSFERASE; EXPLORATORY BEHAVIOR; FEMALE; GENE TARGETING; HUMANS; LEARNING; MALE; MEMORY; METHIONINE; MICE; MICE, TRANSGENIC; MODELS, ANIMAL; POLYMORPHISM, SINGLE NUCLEOTIDE; PREPULSE INHIBITION; SEX FACTORS; VALINE;

EID: 84902550542     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.29     Document Type: Article

References (69)

1. Barnett JH, Jones PB, Robbins TW, Muller U (2007). Effects of the catechol-O-methyltransferase Val158Met polymorphism on executive function: a meta-analysis of the Wisconsin Card Sort Test in schizophrenia and healthy controls. Mol Psychiatry 12: 502.
2. Barnett JH, Scoriels L, Munaf AMR (2008). Meta-analysis of the cognitive effects of the Catechol-O-Methyltransferase Gene Val158/108Met polymorphism. Biol Psychiatry 64: 137-144.
3. Bilder RM, Volavka J, Lachman HM, Grace AA (2004). The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 29: 1943-1961.
4. Bontempi B, Whelan KT, Risbrough VB, Lloyd GK, Menzaghi F (2003). Cognitive enhancing properties and tolerability of cholinergic agents in mice: a comparative study of nicotine, donepezil, and SIB-1553A, a subtype-selective ligand for nicotinic acetylcholine receptors. Neuropsychopharmacology 28: 1235-1246.
5. Boscarino JA, Erlich PM, Hoffman SN, Rukstalis M, Stewart WF (2011). Association of FKBP5, COMT and CHRNA5 polymorphisms with PTSD among outpatients at risk for PTSD. Psychiatry Res 188: 173-174.
6. Buckert M, Kudielka BM, Reuter M, Fiebach CJ (2012). The COMT Val158Met polymorphism modulates working memory performance under acute stress. Psychoneuroendocrinology 37: 1810-1821.
7. Caldu X, Vendrell P, Bartres-Faz D, Clemente I, Bargallo N, Jurado MA et al (2007). Impact of the COMT Val108/158 Met and DAT genotypes on prefrontal function in healthy subjects. Neuroimage 37: 1437-1444.
8. Chavez C, Hollaus M, Scarr E, Pavey G, Gogos A, van den Buuse M (2010). The effect of estrogen on dopamine and serotonin receptor and transporter levels in the brain: an autoradiography study. Brain Res 1321: 51-59.
9. Chen CY, Lu RB, Yeh YW, Shih MC, Huang SY (2011a). Association study of catechol-O-methyltransferase gene polymorphisms with schizophrenia and psychopathological symptoms in Han Chinese. Genes Brain Behav 10: 316-324.
10. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S et al (2004). Functional analysis of genetic variation in catechol-Omethyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 75: 807-821.
11. Chen J, Song J, Yuan P, Tian Q, Ji Y, Ren-Patterson R et al (2011b). Orientation and cellular distribution of membrane-bound catechol-O- methyltransferase in cortical neurons: implications for drug development. J Biol Chem 286: 34752-34760.
12. Diaz-Asper CM, Goldberg TE, Kolachana BS, Straub RE, Egan MF, Weinberger DR (2008). Genetic variation in catechol-O-methyltransferase: effects on working memory in schizophrenic patients, their siblings, and healthy controls. Biol Psychiatry 63: 72-79.
13. Drabant EM, Hariri AR, Meyer-Lindenberg A, Munoz KE, Mattay VS, Kolachana BS et al (2006). Catechol O-methyltransferase val158met genotype and neural mechanisms related to affective arousal and regulation. Arch Gen Psychiatry 63: 1396-1406.
14. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE et al (2001). Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 98: 6917-6922.
15. Fan JB, Zhang CS, Gu NF, Li XW, Sun WW, Wang HY et al (2005). Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: a large-scale association study plus meta-analysis. Biol Psychiatry 57: 139-144.
16. Farrell SM, Tunbridge EM, Braeutigam S, Harrison PJ (2012). COMT Val(158)Met genotype determines the direction of cognitive effects produced by catechol-O-methyltransferase inhibition. Biol Psychiatry 71: 538-544.
17. Gamo NJ, Arnsten AF (2011). Molecular modulation of prefrontal cortex: rational development of treatments for psychiatric disorders. Behav Neurosci 125: 282-296.
18. Geyer MA, Russo PV, Masten VL (1986). Multivariate assessment of locomotor behavior: pharmacological and behavioral analyses. Pharmacol Biochem Behav 25: 277-288.
19. Giakoumaki SG, Roussos P, Bitsios P (2008). Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism. Neuropsychopharmacology 33: 3058-3068.
20. Glatt SJ, Faraone SV, Tsuang MT (2003). Association between a functional catechol O-methyltransferase gene polymorphism and schizophrenia: meta-analysis of case-control and familybased studies. Am J Psychiatry 160: 469-476.
21. Gogos A, Kwek P, Chavez C, van den Buuse M (2010). Estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine- induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2 or serotonin 5-HT1A, 5-HT2A, or 5- HT7 receptors. J Pharmacol Exp Ther 333: 218-227.
22. Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D et al (1998a). Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci U S A 95: 9991-9996.
23. Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D et al (1998b). Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. PNAS 95: 9991-9996.
24. Gothelf D, Eliez S, Thompson T, Hinard C, Penniman L, Feinstein C et al (2005). COMT genotype predicts longitudinal cognitive decline and psychosis in 22q11.2 deletion syndrome. Nat Neurosci 8: 1500.
25. Gresack JE, Risbrough VB (2011). Corticotropin-releasing factor and noradrenergic signalling exert reciprocal control over startle reactivity. Int J Neuropsychopharmacol 14: 1179-1194.
26. Gresack JE, Risbrough VB, Scott CN, Coste S, Stenzel-Poore M, Geyer MA et al (2010). Isolation rearing-induced deficits in contextual fear learning do not require CRF2 receptors. Behav Brain Res 209: 80-84.
27. Huotari M, Gogos JA, Karayiorgou M, Koponen O, Forsberg M, Raasmaja A et al (2002). Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice. Eur J Neurosci 15: 246-256.
28. Kim M, Soontornniyomkij V, Ji B, Zhou X (2012). System-wide immunohistochemical analysis of protein co-localization. PLoS One 7: e32043.
29. Kolassa I-T, Kolassa S, Ertl V, Papassotiropoulos A, De Quervain DJF (2010). The risk of posttraumatic stress disorder after trauma depends on traumatic load and the catechol-O-methyltransferase Val158Met polymorphism. Biol Psychiatry 67: 304-308.
30. Laatikainen LM, Sharp T, Harrison PJ, Tunbridge EM (2013). Sexually dimorphic effects of catechol-O-methyltransferase (COMT) inhibition on dopamine metabolism in multiple brain regions. PLoS One 8: e61839.
31. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM (1996). Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6: 243-250.
32. Lalonde R (2002). The neurobiological basis of spontaneous alternation. Neurosci Biobehav Rev 26: 91-104.
33. Lonsdorf TB, Ruck C, Bergstrom J, Andersson G, Ohman A, Lindefors N et al (2010). The COMTval158met polymorphism is associated with symptom relief during exposure-based cognitive-behavioral treatment in panic disorder. BMC Psychiatry 10: 99.
34. Lonsdorf TB, Weike AI, Nikamo P, Schalling M, Hamm AO, Ohman A (2009). Genetic gating of human fear learning and extinction: possible implications for gene-environment interaction in anxiety disorder. Psychol Sci 20: 198-206.
35. Matsumoto M, Weickert CS, Akil M, Lipska BK, Hyde TM, Herman MM et al (2003). Catechol O-methyltransferase mRNA expression in human and rat brain: evidence for a role in cortical neuronal function. Neuroscience 116: 127-137.
36. Montag C, Hartmann P, Merz M, Burk C, Reuter M (2008). D2 receptor density and prepulse inhibition in humans: negative findings from a molecular genetic approach. Behav Brain Res 187: 428-432.
37. Murphy KC, Jones LA, Owen MJ (1999a). High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry 56: 940-945.
38. Murphy KC, Jones LA, Owen MJ (1999b). High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry 56: 940-945.
39. Nieratschker V, Frank J, Muhleisen TW, Strohmaier J, Wendland JR, Schumacher J et al (2010). The catechol-O-methyl transferase (COMT) gene and its potential association with schizophrenia: findings from a large German case-control and family-based sample. Schizophr Res 122: 24-30.
40. Norrholm SD, Jovanovic T, Olin IW, Sands LA, Karapanou I, Bradley B et al (2011). Fear extinction in traumatized civilians with posttraumatic stress disorder: relation to symptom severity. Biol Psychiatry 69: 556-563.
41. Norrholm SD, Jovanovic T, Smith A, Binder EB, Klengel T, Conneely K et al (2013). Differential genetic and epigenetic regulation of catechol-O-methyl- transferase (COMT) is associated with impaired fear inhibition in posttraumatic stress disorder. Front Behav Neurosci 7: 1-10.
42. Orsini CA, Maren S (2012). Neural and cellular mechanisms of fear and extinction memory formation. Neurosci Biobehav Rev 36: 1773-1802.
43. Palmatier MA, Kang AM, Kidd KK (1999). Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles. Biol Psychiatry 46: 557-567.
44. Papaleo F, Crawley JN, Song J, Lipska BK, Pickel J, Weinberger DR et al (2008a). Genetic dissection of the role of catechol-Omethyltransferase in cognition and stress reactivity in mice. J Neurosci 28: 8709-8723.
45. Papaleo F, Crawley JN, Song J, Lipska BK, Pickel J, Weinberger DR et al (2008b). Genetic dissection of the role of catechol-Omethyltransferase in cognition and stress reactivity in mice. J Neurosci 28: 8709-8723.
46. Papaleo F, Erickson L, Liu G, Chen J, Weinberger DR (2012). Effects of sex and COMT genotype on environmentally modulated cognitive control in mice. Proc Natl Acad Sci 109: 20160-20165.
47. Papaleo F, Burdick MC, Callicott JH, Weinberger DR (2013). Epistatic interaction between COMT and DTNBP1 modulates prefrontal function in mice and in humans. Mol Psychiatry 19: 311-316.
48. Quednow BB, Schmechtig A, Ettinger U, Petrovsky N, Collier DA, Vollenweider FX et al (2009). Sensorimotor gating depends on polymorphisms of the serotonin-2A receptor and catechol-Omethyltransferase, but not on neuregulin-1 Arg38Gln genotype: a replication study. Biol Psychiatry 66: 614-620.
49. Quednow BB, Wagner M, Mossner R, Maier W, Kuhn KU (2008). Sensorimotor gating of schizophrenia patients depends on catechol O-methyltransferase Val158Met polymorphism. Schizophr Bull 36: 341-346.
50. Raznahan A, Greenstein D, Lee Y, Long R, Clasen L, Gochman P et al (2011). Catechol-o-methyl transferase (COMT) val158met polymorphism and adolescent cortical development in patients with childhood-onset schizophrenia, their non-psychotic siblings, and healthy controls. Neuroimage 57: 1517-1523.
51. Risbrough VB, Masten VL, Caldwell S, Paulus MP, Low MJ, Geyer MA (2006). Differential contributions of dopamine D1, D2, and D3 receptors to MDMA-induced effects on locomotor behavior patterns in mice. Neuropsychopharmacology 31: 2349-2358.
52. Rolls ET, Loh M, Deco G, Winterer G (2008). Computational models of schizophrenia and dopamine modulation in the prefrontal cortex. Nat Rev Neurosci 9: 696-709.
53. Roussos P, Giakoumaki SG, Rogdaki M, Pavlakis S, Frangou S, Bitsios P (2008). Prepulse inhibition of the startle reflex depends on the catechol O-methyltransferase Val158Met gene polymorphism. Psychol Med 38: 1651-1658.
54. Sheynikhovich D, Otani S, Arleo A (2013). Dopaminergic control of long-term depression/long-term potentiation threshold in prefrontal cortex. The Journal of Neuroscience 33: 13914-13926.
55. Smolka MN, Schumann G, Wrase J, Grusser SM, Flor H, Mann K et al (2005). Catechol-O-methyltransferase val158met genotype affects processing of emotional stimuli in the amygdala and prefrontal cortex. J Neurosci 25: 836-842.
56. Swerdlow NR, Geyer MA, Braff DL (2001). Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl) 156: 194-215.
57. Swerdlow NR, Shoemaker JM, Auerbach PP, Pitcher L, Goins J, Platten A (2004). Heritable differences in the dopaminergic regulation of sensorimotor gatingII. Temporal, pharmacologic and generational analyses of apomorphine effects on prepulse inhibition. Psychopharmacology (Berl) 174: 452-462.
58. Swerdlow NR, Weber M, Qu Y, Light GA, Braff DL (2008). Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology (Berl) 199: 331-388.
59. Toth M, Gresack JE, Bangasser DA, Plona Z, Valentino RJ, Flandreau EI et al (2014). Forebrain-specific CRF over-production during development is sufficient to induce enduring anxiety and startle abnormalities in adult mice. Neuropsychopharmacology.
60. Tsao D, Wieskopf JS, Rashid N, Sorge RE, Redler RL, Segall SK et al (2012). Serotonin-induced hypersensitivity via inhibition of catechol O-methyltransferase activity. Mol Pain 8: 25.
61. Tunbridge EM, Bannerman DM, Sharp T, Harrison PJ (2004). Catechol-o-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex. J Neurosci 24: 5331-5335.
62. Tunbridge EM, Harrison PJ (2011). Importance of the COMT gene for sex differences in brain function and predisposition to psychiatric disorders. Curr Top Behav Neurosci 8: 119-140.
63. Tunbridge EM, Harrison PJ, Weinberger DR (2006). Catechol- omethyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry 60: 141-151.
64. Valente No, Vallada H, Cordeiro Q, Bressan R, Andreoli S, Mari J et al (2011). Catechol-O-methyltransferase (COMT) val158met polymorphism as a risk factor for PTSD after urban violence. J Mol Neurosci 43: 516-523.
65. Wang Y, Li J, Chen C, Chen C, Zhu B, Moysis RK et al (2013). COMT rs4680 Met is not always the 'smart allele': Val allele is associated with better working memory and larger hippocampal volume in healthy Chinese. Genes Brain Behav 12: 323-329.
66. Williams HJ, Glaser B, Williams NM, Norton N, Zammit S, MacGregor S et al (2005). No association between schizophrenia and polymorphisms in COMT in two large samples. Am J Psychiatry 162: 1736-1738.
67. Witte AV, Floel A (2012). Effects of COMT polymorphisms on brain function and behavior in health and disease. Brain Res Bull 88: 418-428.
68. Young JW, Wallace CK, Geyer MA, Risbrough VB (2010). Ageassociated improvements in cross-modal prepulse inhibition in mice. Behav Neurosci 124: 133-140.
69. Zhou X, Benson KF, Ashar HR, Chada K (1995). Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 376: 771-774.